The US Food and Drug Administration has drawn a lot of negative attention in recent years for approving drugs like Alzheimer’s treatment Aduhelm over the objection of its outside advisers. But this type of controversial decision by FDA is fairly rare.
FDA and its advisory panels usually agree and when they don’t, the agency is more likely to take more conservative actions than its committees — declining to approve drugs its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?